Last week, AbbVie Inc. (NYSE:ABBV) announced that it has initiated a phase III study on its oncology candidate, veliparib in patients suffering from human epidermal growth factor receptor 2 (HER2) negative metastatic or locally advanced breast cancer, containing BRCA1 (breast cancer gene 1) and/or BRCA2 (breast cancer gene 2) mutations. AbbVie Inc. (NYSE:ABBV) net profit margin is 21.80% and weekly performance is 6.16%. On last trading day company shares ended up $56.89. Analysts mean target price for the company is $58.00. AbbVie Inc. (NYSE:ABBV) distance from 50-day simple moving average (SMA50) is 7.00%.
Galena Biopharma Inc. (NASDAQ:GALE) announced the notice of allowance of a U.S. Patent for NeuVax (nelipepimut-S) covering the use of NeuVax alone or in combination to prevent recurrence of any HER2/neu expressing tumor having a fluorescence in situ hybridization (FISH) rating of less than about 2.0. NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena’s lead development agent in multiple ongoing and planned clinical trials. Once issued, the patent will expire in 2028, not including any patent term extensions. Galena Biopharma Inc. (NASDAQ:GALE) shares advanced 6.21% in last trading session and ended the day on $3.25. GALE gross Margin is 80.90% and its return on assets is -95.00%.Galena Biopharma Inc. (NASDAQ:GALE) quarterly performance is 26.95%.
Minneapolis-based Medtronic Inc. (NYSE:MDT) agreed to purchase Covidien PLC for $43 billion and reincorporate in Ireland, which would lower Medtronic’s tax rate and allow the company to access its $12 billion in cash held offshore without paying U.S. taxes. Medtronic, Inc. (NYSE:MDT) shares moved up 0.72% in last trading session and was closed at $63.91, while trading in range of $63.20 – $64.07. Medtronic, Inc. (NYSE:MDT) year to date (YTD) performance is 11.87%.
Bristol-Myers Squibb (NYSE:BMY) Companydisclaimer icon is voluntarily recalling six lots of COUMADIN® FOR INJECTION, 5 mg single-use vials in the U.S. This recall is a precautionary measure based on the company’s investigation of visible particulate matter found in a small number of COUMADIN FOR INJECTION unreleased samples. Bristol-Myers Squibb Co (NYSE:BMY) ended the last trading day at $48.12. Company weekly volatility is calculated as 1.63% and price to cash ratio as 11.30.Bristol-Myers Squibb Co (NYSE:BMY) showed a negative weekly performance of -0.37%.
Agenus Inc. (NASDAQ:AGEN) announced phase 2 trial results of its Prophage autologous cancer vaccine for glioblastoma multiforme (GBM) today. The results showed that patients who were administered the vaccine as part of their standard care treatment saw an astonishing 2-year increase in their life spans. The results carry significance because in a majority of cases, the disease tends to kill patients within a year. Agenus Inc. (NASDAQ:AGEN) weekly performance is 4.72%. On last trading day company shares ended up $3.55. Analysts mean target price for the company is $7.00. Agenus Inc. (NASDAQ:AGEN) distance from 50-day simple moving average (SMA50) is 18.90%.
Leave a Reply